Sanofi (NYSE:SNY) Analyst Rating Consensus

Sanofi (NYSE:SNY) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.8 by 5 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. Equity analysts at the Brokerage firm Barclays upgrades its rating on Sanofi (NYSE:SNY). The rating major has initiated the coverage with overweight rating on the shares. Earlier, the shares were rated a Equal-weight by the brokerage firm. The rating by the firm was issued on May 12, 2016.

Sanofi (NYSE:SNY): According to 2 Analysts, The short term target price has been estimated at $ 55.5.The target price could deviate by a maximum of $3.54 from the forecast price. In the near term, the target price could hit a high of $58 and a low of $ 53.

Sanofi (NYSE:SNY) rose 1.76% or 0.69 points on Tuesday and made its way into the gainers of the day. After trading began at $39.61 the stock was seen hitting $39.94 as a peak level and $39.32 as the lowest level. The stock ended up at $39.79. The daily volume was measured at 1,765,571 shares. The 52-week high of the share price is $54.98 and the 52-week low is $37.41. The company has a market cap of $103,907 million.

Shares of Sanofi appreciated by 4.35% during the last five trading days but lost 0.38% on a 4-week basis. Sanofi is up 3.92% in the last 3-month period. Year-to-Date the stock performance stands at -2.78%.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.